A longitudinal study of 4 cohorts of patients with psoriasis and psoriatic arthritis: one treated with Otezla (apremilast), one with an injectable comparator drug, one with an oral comparator drug and one with an oral and an injectable comparator drug (Otezla-CPRD-001)